Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

RCT reported improved progression-free survival with surufatinib, vs placebo (n=172; 10.9 vs 3.7 months; HR 0.49, 95% CI 0.32–0.76; p=0.0011). Most common grade 3 adverse events were hypertension (38% vs 7%), proteinuria (10% vs 2%) and hypertriglyceridaemia (7% vs none).

SPS commentary:

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor and fibroblast growth factor receptor.

The phase III SANET-ep RCT reported improved progression-free in advanced extrapancreatic neuroendocrine tumours treated with surufatinib vs placebo (n=192; 9.2 vs 3.8 months; HR 0.33; 95% CI 0.22–0.50; p<0.0001).


The Lancet Oncology

Resource links: